
|Articles|February 1, 2001
CME: Offering mifepristone as an abortion option
While family planning clinics are hailing the FDA's recent approval of mifepristone (RU-486) as a noninvasive way to terminate an unwanted pregnancy, ob/gyns who decide to administer the drug need to familiarize themselves with the research on its advantages and disadvantages.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
GLP-1 RAs linked to broad menstrual adverse event signals in reproductive-aged patients
2
A discussion of STI rates, barriers, and home screenings with Damian Alagia III, MD
3
Q+A: Connor Frey, MD, on GLP-1 RAs and menstrual adverse event signals
4
Statewide bundle reduces risk for deliveries complicated by postpartum hemorrhage
5





